Product nameAnti-CYLD antibody
See all CYLD primary antibodies
DescriptionRabbit polyclonal to CYLD
Tested applicationsSuitable for: WB, IHC-P, ICC/IFmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat, Cow, Xenopus tropicalis
- 293T, H1299, HeLa, HepG2, A431 and Raji whole cell lysates; A431 cells; Human gastric carcinoma tissue.
Storage instructionsShipped at 4°C. Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.00
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: PBS, 20% Glycerol
Concentration information loading...
PurityImmunogen affinity purified
- HepG2 cytoplasmic extract lysate (ab14659)
- HeLa whole cell lysate (ab29545)
- HeLa membrane extract lysate (ab29547)
- Raji whole cell lysate (ab30124)
- Raji membrane extract lysate (ab30126)
- A431 whole cell lysate (ab30132)
- A431 membrane extract lysate (ab30134)
- HepG2 whole cell lysate (ab7900)
- A431 whole cell lysate (ab7909)
- 293T whole cell lysate (ab95494)
Our Abpromise guarantee covers the use of ab137524 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/3000. Predicted molecular weight: 107 kDa.|
|IHC-P||1/100 - 1/1000. Perform heat mediated antigen retrieval before commencing with IHC staining protocol using 10mM Citrate buffer (pH6.0) or Tris-EDTA buffer (pH8.0).|
|ICC/IF||1/100 - 1/1000.|
FunctionProtease that specifically cleaves 'Lys-63'-linked polyubiquitin chains. Has endodeubiquitinase activity. Plays an important role in the regulation of pathways leading to NF-kappa-B activation. Contributes to the regulation of cell survival, proliferation and differentiation via its effects on NF-kappa-B activation. Negative regulator of Wnt signaling. Inhibits HDAC6 and thereby promotes acetylation of alpha-tubulin and stabilization of microtubules. Plays a role in the regulation of microtubule dynamics, and thereby contributes to the regulation of cell proliferation, cell polarization, cell migration, and angiogenesis. Required for normal cell cycle progress and normal cytokinesis. Inhibits nuclear translocation of NF-kappa-B. Plays a role in the regulation of inflammation and the innate immune response, via its effects on NF-kappa-B activation. Dispensable for the maturation of intrathymic natural killer cells, but required for the continued survival of immature natural killer cells. Negatively regulates TNFRSF11A signaling and osteoclastogenesis.
Tissue specificityDetected in fetal brain, testis, and skeletal muscle, and at a lower level in adult brain, leukocytes, liver, heart, kidney, spleen, ovary and lung. Isoform 2 is found in all tissues except kidney.
Involvement in diseaseDefects in CYLD are the cause of familial cylindromatosis (FCYL) [MIM:132700]; also known as Ancell-Spiegler cylindromas or turban tumor syndrome or dermal eccrine cylindromatosis. CYLD is an autosomal dominant and highly tumor type-specific disorder. The tumors (known as cylindromas because of their characteristic microscopic architecture) are believed to arise from or recapitulate the appearance of the eccrine or apocrine cells of the skin that secrete sweat and scent respectively. Cylindromas arise predominantly in hairy parts of the body with approximately 90% on the head and neck. The development of a confluent mass which may ulcerate or become infected has led to the designation 'turban tumor syndrome'. The skin tumors show differentiation in the direction of hair structures, hence the synonym trichoepithelioma.
Defects in CYLD are the cause of multiple familial trichoepithelioma type 1 (MFT1) [MIM:601606]; also known as epithelioma adenoides cysticum of Brooke (EAC) or hereditary multiple benign cystic epithelioma or Brooke-Fordyce trichoepitheliomas. MFT1 is an autosomal dominant dermatosis characterized by the presence of many skin tumors predominantly on the face. Since histologic examination shows dermal aggregates of basaloid cells with connection to or differentiation toward hair follicles, this disorder has been thought to represent a benign hamartoma of the pilosebaceous apparatus. Trichoepitheliomas can degenerate into basal cell carcinoma.
Defects in CYLD are the cause of Brooke-Spiegler syndrome (BRSS) [MIM:605041]. BRSS is an autosomal dominant disorder characterized by the appearance of multiple skin appendage tumors such as cylindroma, trichoepithelioma, and spiradenoma. These tumors are typically located in the head and neck region, appear in early adulthood, and gradually increase in size and number throughout life.
Sequence similaritiesBelongs to the peptidase C67 family.
Contains 3 CAP-Gly domains.
modificationsPhosphorylated on several serine residues by IKKA and/or IKKB in response to immune stimuli. Phosphorylation requires IKBKG. Phosphorylation abolishes TRAF2 deubiquitination, interferes with the activation of Jun kinases, and strongly reduces CD40-dependent gene activation by NF-kappa-B.
Cellular localizationCytoplasm. Cytoplasm > perinuclear region. Cytoplasm > cytoskeleton. Cell membrane. Detected at the microtubule cytoskeleton during interphase. Detected at the midbody during telophase.
- Information by UniProt
- BRSS antibody
- CDMT antibody
- Cyld antibody
Anti-CYLD antibody (ab137524) at 1/1000 dilution + HepG2 whole cell lysate at 30 µg
Predicted band size: 107 kDa
7.5% SDS PAGE
Immunohistochemical analysis of paraffin embedded Human gastric carcinoma tissue labelling CYLD with ab137524 at 1/100 dilution.
Immunofluorescent analysis of paraformaldehyde-fixed A431 cells labelling CYLD with ab137524 at 1/200 dilution. The lower image is merged with DNA probe.
This product has been referenced in:
- Chen Y & Yang C miR-197-3p-induced downregulation of lysine 63 deubiquitinase promotes cell proliferation and inhibits cell apoptosis in lung adenocarcinoma cell lines. Mol Med Rep 17:3921-3927 (2018). Read more (PubMed: 29286108) »
- Liu H et al. Alterations of 63 hub genes during lingual carcinogenesis in C57BL/6J mice. Sci Rep 8:12626 (2018). Read more (PubMed: 30135512) »